Current options for the prevention and treatment of migraine

被引:33
作者
Adelman, JU
Adelman, RD
机构
[1] Headache Wellness Ctr, Greensboro, NC 27401 USA
[2] Private Practice, Raleigh, NC USA
关键词
5-HT1B/1D-receptor agonists; triptans; analgesic; headache; migraine;
D O I
10.1016/S0149-2918(01)80069-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Migraine is a common condition affecting similar to 18% of women and 6% of men in the United States. The goals of managing migraine are 2-fold: to prevent attacks from occurring and to effectively and rapidly end them when they do occur. Objective: This article reviews the acute and prophylactic treatment of migraine. Methods: Information for inclusion in this review was identified through a search of MEDLINE(R) from 1995 to the present. Search terms included migraine, acute treatment, prophylactic treatment, preventive treatment, and individual drug names. Results: Preventive measures for migraine include lifestyle changes (eg, avoiding migraine triggers and maintaining regular sleep, eating, and work habits) and drug therapy. Beta-blockers, calcium channel blockers, tricyclic antidepressants, and anticonvulsants are among the more common drug classes used for migraine prophylaxis, but preventive therapy must be individualized, taking into account efficacy, potential adverse effects, coexisting medical conditions, and drug costs. Many medications are available for the acute treatment of migraine, including over-the-counter analgesics and prescription drugs. Of the latter, the 5-hydroxytryptaminc(1B/1D)-receptor agonists, or triptans, are the most recently introduced class. Each of the 4 available triptans (sumatriptan, zolmitriptan, naratriptan, and rizatriptan) is effective in ending a migraine attack, but comparative trials have shown differences between individual drugs in the time to pain relief and the percentage of patients who obtain pain relief. Conclusions: Medications to prevent or reduce the frequency of migraine tend to be less specific and effective than medications for the acute treatment of migraine. As a class, triptans are generally well tolerated and may be considered drugs of choice for the acute treatment of moderate to severe migraine.
引用
收藏
页码:772 / 788
页数:17
相关论文
共 58 条
  • [1] Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting
    Adelman, LC
    Adelman, JU
    Von Seggern, R
    Mannix, LK
    [J]. HEADACHE, 2000, 40 (07): : 572 - 580
  • [2] Triptans and migraine
    Bateman, DN
    [J]. LANCET, 2000, 355 (9207) : 860 - 861
  • [3] Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine
    Bomhof, M
    Paz, J
    Legg, N
    Allen, C
    Vandormael, K
    Patel, K
    [J]. EUROPEAN NEUROLOGY, 1999, 42 (03) : 173 - 179
  • [4] Boureau F, 2000, INT J CLIN PRACT, V54, P281
  • [5] Bussone G, 1999, CEPHALALGIA, V19, P232
  • [6] Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials
    Cady, RK
    Sheftell, F
    Lipton, RB
    O'Quinn, S
    Jones, M
    Putnam, DG
    Crisp, A
    Metz, A
    McNeal, S
    [J]. CLINICAL THERAPEUTICS, 2000, 22 (09) : 1035 - 1048
  • [7] Cady RK, 1999, NEUROLOGY, V52, pA205
  • [8] INTRAVENOUS CHLORPROMAZINE VS INTRAVENOUS METOCLOPRAMIDE IN ACUTE MIGRAINE HEADACHE
    CAMERON, JD
    LANE, PL
    SPEECHLEY, M
    [J]. ACADEMIC EMERGENCY MEDICINE, 1995, 2 (07) : 597 - 602
  • [9] An overview of the diagnosis and pharmacologic treatment of migraine
    Capobianco, DJ
    Cheshire, WP
    Campbell, JK
    [J]. MAYO CLINIC PROCEEDINGS, 1996, 71 (11) : 1055 - 1066
  • [10] RANDOMIZED, PLACEBO-CONTROLLED EVALUATION OF PROCHLORPERAZINE VERSUS METOCLOPRAMIDE FOR EMERGENCY DEPARTMENT TREATMENT OF MIGRAINE HEADACHE
    COPPOLA, M
    YEALY, DM
    LEIBOLD, RA
    [J]. ANNALS OF EMERGENCY MEDICINE, 1995, 26 (05) : 541 - 546